Evidence map›Paper›PMID 25368986›Full record

ArticlePloS one2014

High efficiency ex vivo cloning of antigen-specific human effector T cells.

Michelle A Neller, Michael H-L Lai, Catherine M Lanagan, Linda E O'Connor, Antonia L Pritchard, Nathan R Martinez, Christopher W Schmidt

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Human CD4Cancer immunology research · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michelle A NellerCancer Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; School of Medicine, The University of Queensland Mayne Medical School, Brisbane, Queensland, Australia.
Michael H-L LaiCancer Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Catherine M LanaganCancer Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Linda E O'ConnorCancer Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Antonia L PritchardOncogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Nathan R MartinezCancer Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Christopher W SchmidtCancer Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While cloned T cells are valuable tools for the exploration of immune responses against viruses and tumours, current cloning methods do not allow inferences to be made about the function and phenotype of a clone's in vivo precursor, nor can precise cloning efficiencies be calculated. Additionally, there is currently no general method for cloning antigen-specific effector T cells directly from peripheral blood mononuclear cells, without the need for prior expansion in vitro. Here we describe an efficient method for cloning effector T cells ex vivo. Functional T cells are detected using optimised interferon gamma capture following stimulation with viral or tumour cell-derived antigen. In combination with multiple phenotypic markers, single effector T cells are sorted using a flow cytometer directly into multi-well plates, and cloned using standard, non antigen-specific expansion methods. We provide examples of this novel technology to generate antigen-reactive clones from healthy donors using Epstein-Barr virus and cytomegalovirus as representative viral antigen sources, and from two melanoma patients using autologous melanoma cells. Cloning efficiency, clonality, and retention/loss of function are described. Ex vivo effector cell cloning provides a rapid and effective method of deriving antigen-specific T cells clones with traceable in vivo precursor function and phenotype.

Indexed as

Amino Acid SequenceAntigens, NeoplasmAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationCells, CulturedCytomegalovirusEnzyme-Linked Immunosorbent AssayFlow CytometryHerpesvirus 4, HumanHumansInterferon-gammaLeukocytes, MononuclearMolecular Sequence DataT-Lymphocytes, CytotoxicAntigens, NeoplasmAntigens, ViralInterferon-gamma

Identifiers

PMID25368986
PMCPMC4219695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.